Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025
   Review
2. Global Prevalence of Preexisting Antibodies against Human Adenoviruses, Surveyed from 1962 to 2021.Intervirology · 2024
   Review
3. mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.Emerging microbes & infections · 2022
   Article
4. Versatile nanorobot hand biosensor for specific capture and ultrasensitive quantification of viral nanoparticles.Materials today. Bio · 2022
   Article
5. Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses.MedComm · 2022
   Article
6. Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.Vaccines · 2022
   Article

Corrections and comments

• Comment on
  Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as